查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1797675

充血消除剂的全球市场:产品类型·处方区分·类别·用途·年龄层·流通管道·各地区 (～2035年)

Global Decongestant Market Research Report by Product Type, by Formulation, by Category, by Application, by Age Group, by Distribution Channel, and by Region Forecast till 2035
出版日期: | 出版商: Market Research Future | 英文 154 Pages | 订单完成后即时交付

价格

全球减充血剂市场预计将从 2024 年的 289.6535 亿美元成长至 2035 年的 578.1082 亿美元，预测期内复合年增长率为 6.48%。

减充血剂透过收缩鼻腔内肿胀组织，暂时缓解鼻塞和鼻塞。它们作用于血管，减轻肿胀，缓解呼吸。减充血剂是一种广泛使用的非处方 (OTC) 药物，用于治疗感冒、过敏性鼻炎和鼻窦相关症状。

呼吸系统疾病仍然是全球主要的健康问题，因此，减充血剂的需求在医疗市场中持续占领先地位。感冒、流感、花粉症和鼻窦炎病例持续上升，城市空气污染更加剧了这个趋势。这促使鼻腔喷剂、口服药物和吸入药物的消费量增加。呼吸道污染物，尤其是PM和NO2，会加剧现有的慢性呼吸系统疾病，促使患者严重依赖减充血剂治疗。这种需求不仅持续存在，而且季节性流行病也加剧了这种需求。随着已开发市场和新兴市场呼吸系统疾病的增多，减充血剂市场作为自我照护医疗解决方案的重要组成部分，正在持续扩张。

区域分析

北美市场得益于零售药局和电商平台广泛供应的减充血剂。鼻窦炎和气喘的高发生率也推动了持续的产品需求。北美市场占强劲地位，预计到2024年将达到109.7578亿美元，这反映了其先进的分销网络以及消费者对季节性过敏减充血剂的高度依赖。

欧洲对减充血剂的需求正在增长，由于寒冷天气，呼吸系统疾病在欧洲普遍存在。鼻喷剂、滴剂和口服减充血剂透过强大的医药供应链持续供应。欧洲市场预计到2024年将达到86.4187亿美元，由于自我照护行为的增加以及支持非处方药的立法，其需求保持稳定。

随着空气污染成为呼吸系统疾病的主要原因，亚太地区正在迅速扩张。非处方药在东南亚和印度的中产阶级群体中越来越受欢迎。亚太市场规模预计在 2024 年达到 6,967,030,000 美元，随着城市化和收入水平的提高，非处方和处方减充血剂的使用量不断增加，该市场正在经历快速增长。

本报告研究了全球减充血剂市场，并提供了市场定义和概述、影响市场成长的各种因素分析、市场规模趋势和预测、按细分市场、地区和主要国家/地区进行的细分、竞争格局以及主要公司的概况。

目录

第1章 摘要整理

第2章 市场简介

第3章 调查手法

第4章 市场动态

  • 促进因素
    • 呼吸系统疾病发生率不断上升
    • 自我药疗日益普及
  • 阻碍因素
    • 严格的监管准则
    • 减充血剂的副作用与安全问题
  • 机遇
    • 对天然和草药减充血剂的需求不断增长
    • 针对多种疾病的联合疗法的开发症状
  • COVID-19影响分析

第5章 市场要素分析

  • 供应链/价值链分析
  • 波特的五力分析

第6章 全球充血消除剂市场:各产品类型

  • 合成充血消除剂
  • 芳香性充血消除剂
  • 药草充血消除剂
  • 并用剂

第7章 全球充血消除剂市场:处方各种类

  • 鼻腔
  • 口服
  • 局部

第8章 全球充血消除剂市场:各类别

  • 处方药
  • OTC药

第9章 全球充血消除剂市场:各用途

  • 过敏性鼻炎
  • 感冒
  • 气喘
  • 鼻炎
  • 鼻窦炎
  • 鼻子息肉
  • 其他

第10章 全球充血消除剂市场:各年龄层

  • 小儿科
  • 老年医学

第11章 全球充血消除剂市场:各流通管道

  • 医院药局
  • 药妆店·药局
  • 线上药局

第12章 全球充血消除剂市场:各地区

  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东·非洲

第13章 竞争情形

  • 市场占有率分析

第14章 企业简介

  • PFIZER.
  • CIPLA LTD.
  • GLAXOSMITHKLINE(GSK)/PANADOL
  • JOHNSON & JOHNSON
  • APTARGROUP, INC.
  • PROCTOR & GAMBLE COMPANY
  • RECKITT BENCKISER GROUP PLC
  • SANOFI
  • PERRIGO COMPANY PLC
  • DR. REDDY'S LABORATORIES

第15章 资料的引用

Product Code: MRFR/HC/57888-CR

Global Decongestant Market Research Report by Product Type (Synthetic Decongestants, Aromatic Decongestants, Herbal Decongestants, Combination), by Formulation (Nasal, Oral, Topical), by Category (Prescription Based, Over the Counter), by Application (Nasal Allergies, Cold, Asthma, Rhinits, Sinusitis, Nasal Polyps, Others), by Age Group (Peditrics, Adults, Geriatrics), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035

Industry Overview

The global decongestant market will witness steady growth, increasing from USD 28,965.35 million in 2024 to USD 57,810.82 million in 2035, at a 6.48% CAGR throughout 2025-2035. Decongestants are drugs that provide temporary relief from blocked or stuffy noses by shrinking swollen tissues inside the nasal passages. They target blood vessels to reduce swelling and allow easier breathing. Widely sold as over-the-counter remedies, they are used for common colds, allergic rhinitis, and sinus-related issues.

Respiratory diseases are still among the major health concerns all over the earth, which is the reason why the need for decongestants still holds the highest place in the healthcare market. The rising frequency of colds, flu, hay fever, and sinus infections, which is a trend that has been going on for a while and worsened by urban air pollution, has been driving the consumption of nasal sprays, oral tablets, and inhalers. Respiratory pollutants such as PM and NO2 are tailored to trigger the already chronic respiratory disorders in patients who thus rely heavily on decongestant therapies. The demand is not only persistent but also augmented by seasonal outbreaks. The market for healthcare continues to expand as a necessary segment of self-care healthcare solutions, as respiratory cases surge in both developed and underdeveloped worlds.

Key Company Development

Sanofi takes significant steps in the decongestant industry with innovation and strategic expansion. They are stimulating their R&D efforts to attract the launch of the very first photo-sensitive formulations, including variants of multi-symptom combination therapies and natural decongestants. The trend with consumers towards safety and holistic treatment is exactly the direction that the Sanofi company is taking. Sanofi is also leveraging strategic collaborations with healthcare providers and emerging startups to strengthen its position in the growing herbal and alternative remedies segment. To further diversify its portfolio, the company is considering acquisitions of firms with established expertise in natural ingredient-based products.

Key Players

Major players in the global decongestant market are Pfizer, Johnson & Johnson, Sanofi, Cipla Ltd, AptarGroup, Inc., Perrigo Company PLC, PANADOL, and Procter & Gamble Company.

Report Attribute Details

Market Size 2024 USD 28,965.35 Million

Market Size 2035 USD 57,810.82 Million

CAGR (2025-2035) 6.48%

Base Year 2024

Market Forecast Period 2025-2035

Historical Data 2019-2024

Market Segmentations

By Product Type: Synthetic Decongestants - 6.35%, Aromatic Decongestants - 6.56%.

By Formulation: Nasal - 6.61%, Oral - 6.74%.

By Category: Prescription-Based - 6.04%, Over the Counter - 6.64%

By Application: Nasal Allergies - 6.75%, Cold - 6.72%.

By Age Group: Pediatrics - 6.96%, Adults - 6.64%

By Distribution Channel: Hospital Pharmacies - 6.02%, Drug Stores & Retail Pharmacies - 6.62%.

Regional Analysis

The North American market benefits from the widespread availability of decongestants through retail pharmacies and e-commerce platforms. High prevalence of sinusitis and asthma drives consistent product demand. North America's strong position, reaching USD 10,975.78 million in 2024, reflects advanced distribution networks and high consumer reliance on decongestants for seasonal allergies.

Europe's cold weather, which makes respiratory disorders more common, contributes to the continent's need for decongestants. Nasal sprays, drops, and oral decongestants are consistently available because of robust pharmaceutical supply chains. With USD 8,641.87 million, Europe shows consistent demand bolstered by more self-care behaviors and supportive laws for over-the-counter medications.

The market is expanding rapidly in the Asia-Pacific region due to urban air pollution, which is a major cause of respiratory issues. OTC drugs are becoming more and more popular among Southeast Asian and Indian middle-class communities. With a valuation of USD 6,967.03 million, the Asia Pacific market is growing quickly as the usage of over-the-counter and prescription decongestants is increased by urbanization and rising income levels.

South America is showing steady growth, supported by increasing healthcare spending and greater awareness of respiratory treatments. Brazil's large population makes it the dominant market, while Argentina and Chile show growing preference for OTC drugs. Rising internet penetration is also boosting online sales of decongestants.

Rising healthcare expenditure and a growing focus on accessible medicines are driving the MEA market. Gulf Cooperation Council (GCC) countries are emerging as strong contributors with the rapid adoption of modern pharmacy networks. Africa is gradually overcoming barriers of affordability and accessibility, making decongestants more widely available.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 RESEARCH OBJECTIVE
  • 2.3 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
    • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
    • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
  • 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
    • 3.6.1 CONSUMPTION & NET TRADE APPROACH
    • 3.6.2 REVENUE ANALYSIS APPROACH
  • 3.7 DATA FORECASTING
    • 3.7.1 DATA FORECASTING TECHNIQUE
  • 3.8 DATA MODELING
    • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.8.2 DATA MODELING:
  • 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
    • 4.1.1 INNOVATION IN DRUG FORMULATIONS AND DELIVERY SYSTEMS
    • 4.1.2 HEALTHCARE ACCESSIBILITY AND REGULATION
    • 4.1.3 RISING DEMAND FOR NASAL SPRAYS AND INHALERS
  • 4.2 DRIVERS
    • 4.2.1 INCREASING INCIDENCE OF RESPIRATORY DISEASES
    • 4.2.2 GROWING POPULARITY OF SELF-MEDICATION
  • 4.3 RESTRAINTS
    • 4.3.1 STRINGENT REGULATORY GUIDELINES
    • 4.3.2 SIDE EFFECTS AND SAFETY CONCERNS ASSOCIATED WITH DECONGESTANTS
  • 4.4 OPPORTUNITY
    • 4.4.1 INCREASED DEMAND FOR NATURAL AND HERBAL DECONGESTANTS
    • 4.4.2 DEVELOPMENT OF COMBINATION THERAPIES TARGETING MULTIPLE SYMPTOMS
  • 4.5 IMPACT ANALYSIS OF COVID-19
    • 4.5.1 IMPACT ON OVERALL HEALTHCARE
    • 4.5.2 IMPACT ON GLOBAL DECONGESTANT MARKET
    • 4.5.3 IMPACT ON SUPPLY CHAIN OF GLOBAL DECONGESTANT MARKET
    • 4.5.4 IMPACT ON MARKET DEMAND OF GLOBAL DECONGESTANT MARKET
    • 4.5.5 IMPACT ON PRICING OF GLOBAL DECONGESTANT MARKET

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY/VALUE CHAIN ANALYSIS
    • 5.1.1 RAW MATERIAL PROCUREMENT
    • 5.1.2 MANUFACTURING
    • 5.1.3 PACKAGING & LABELLING
    • 5.1.4 DISTRIBUTION AND RETAIL
    • 5.1.5 RETAIL & CONSUMER DEMAND
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 THREAT OF SUBSTITUTES
    • 5.2.3 BARGAINING POWER OF SUPPLIERS
    • 5.2.4 BARGAINING POWER OF BUYERS
    • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL DECONGESTANT MARKET, BY PRODUCT TYPE

  • 6.1 INTRODUCTION
    • 6.1.1 SYNTHETIC DECONGESTANTS
    • 6.1.2 AROMATIC DECONGESTANTS
    • 6.1.3 HERBAL DECONGESTANTS
    • 6.1.4 COMBINATION

7 GLOBAL DECONGESTANT MARKET, BY FORMULATION

  • 7.1 INTRODUCTION
    • 7.1.1 NASAL
      • 7.1.1.1 NASAL SPRAY
      • 7.1.1.2 NASAL DROPS
      • 7.1.1.3 INHALERS
    • 7.1.2 ORAL
      • 7.1.2.1 TABLETS & CAPSULES
      • 7.1.2.2 LIQUIDS & SYRUPS
    • 7.1.3 TOPICAL
      • 7.1.3.1 GELS
      • 7.1.3.2 PATCHES

8 GLOBAL DECONGESTANT MARKET, BY CATEGORY

  • 8.1 INTRODUCTION
    • 8.1.1 PRESCRIPTION-BASED
    • 8.1.2 OVER THE COUNTER

9 GLOBAL DECONGESTANT MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • 9.1.1 NASAL ALLERGIES
    • 9.1.2 COLD
    • 9.1.3 ASTHMA
    • 9.1.4 RHINITIS
    • 9.1.5 SINUSITIS
    • 9.1.6 NASAL POLYPS
    • 9.1.7 OTHERS

10 GLOBAL DECONGESTANT MARKET, BY AGE GROUP

  • 10.1 INTRODUCTION
    • 10.1.1 PEDIATRICS
    • 10.1.2 GERIATRICS

11 GLOBAL DECONGESTANT MARKET, BY DISTRIBUTION CHANNEL

  • 11.1 INTRODUCTION
    • 11.1.1 HOSPITAL PHARMACIES
    • 11.1.2 DRUG STORES & RETAIL PHARMACIES
    • 11.1.3 ONLINE PHARMACIES

12 GLOBAL DECONGESTANT MARKET, BY REGION

  • 12.1 INTRODUCTION
    • 12.1.1 NORTH AMERICA
      • 12.1.1.1 US
      • 12.1.1.2 CANADA
      • 12.1.1.3 MEXICO
    • 12.1.2 EUROPE
      • 12.1.2.1 GERMANY
      • 12.1.2.2 UK
      • 12.1.2.3 FRANCE
      • 12.1.2.4 ITALY
      • 12.1.2.5 SPAIN
      • 12.1.2.6 TURKEY
      • 12.1.2.7 REST OF EUROPE
    • 12.1.3 ASIA-PACIFIC
      • 12.1.3.1 JAPAN
      • 12.1.3.2 CHINA
      • 12.1.3.3 INDIA
      • 12.1.3.4 SOUTH KOREA
      • 12.1.3.5 INDONESIA
      • 12.1.3.6 MALAYSIA
      • 12.1.3.7 AUSTRALIA
      • 12.1.3.8 SINGAPORE
      • 12.1.3.9 REST OF ASIA PACIFIC
    • 12.1.4 SOUTH AMERICA
      • 12.1.4.1 BRAZIL
      • 12.1.4.2 ARGENTINA
      • 12.1.4.3 REST OF SOUTH AMERICA
    • 12.1.5 MIDDLE EAST & AFRICA
      • 12.1.5.1 SOUTH AFRICA
      • 12.1.5.2 GCC COUNTRIES
      • 12.1.5.3 SAUDI ARABIA
      • 12.1.5.4 REST OF MIDDLE EAST AND AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 MARKET SHARE ANALYSIS, 2024

14 COMPANY PROFILES

  • 14.1 PFIZER.
    • 14.1.1 COMPANY OVERVIEW
    • 14.1.2 PRODUCTS OFFERED
    • 14.1.3 SWOT ANALYSIS
    • 14.1.4 KEY STRATEGY
  • 14.2 CIPLA LTD.
    • 14.2.1 COMPANY OVERVIEW
    • 14.2.2 PRODUCTS OFFERED
    • 14.2.3 SWOT ANALYSIS
    • 14.2.4 KEY STRATEGY
  • 14.3 GLAXOSMITHKLINE (GSK)/ PANADOL
    • 14.3.1 COMPANY OVERVIEW
    • 14.3.2 PRODUCTS OFFERED
    • 14.3.3 SWOT ANALYSIS
    • 14.3.4 KEY STRATEGY
  • 14.4 JOHNSON & JOHNSON
    • 14.4.1 COMPANY OVERVIEW
    • 14.4.2 PRODUCTS OFFERED
    • 14.4.3 SWOT ANALYSIS
    • 14.4.4 KEY STRATEGY
  • 14.5 APTARGROUP, INC.
    • 14.5.1 COMPANY OVERVIEW
    • 14.5.2 PRODUCTS OFFERED
    • 14.5.3 SWOT ANALYSIS
    • 14.5.4 KEY STRATEGY
  • 14.6 PROCTOR & GAMBLE COMPANY
    • 14.6.1 COMPANY OVERVIEW
    • 14.6.2 PRODUCTS OFFERED
    • 14.6.3 SWOT ANALYSIS
    • 14.6.4 KEY STRATEGY
  • 14.7 RECKITT BENCKISER GROUP PLC
    • 14.7.1 COMPANY OVERVIEW
    • 14.7.2 PRODUCTS OFFERED
    • 14.7.3 SWOT ANALYSIS
    • 14.7.4 KEY STRATEGY
  • 14.8 SANOFI
    • 14.8.1 COMPANY OVERVIEW
    • 14.8.2 PRODUCTS OFFERED
    • 14.8.3 SWOT ANALYSIS
    • 14.8.4 KEY STRATEGY
  • 14.9 PERRIGO COMPANY PLC
    • 14.9.1 COMPANY OVERVIEW
    • 14.9.2 PRODUCTS OFFERED
    • 14.9.3 SWOT ANALYSIS
    • 14.9.4 KEY STRATEGY
  • 14.10 DR. REDDY'S LABORATORIES
    • 14.10.1 COMPANY OVERVIEW
    • 14.10.2 PRODUCTS OFFERED
    • 14.10.3 SWOT ANALYSIS
    • 14.10.4 KEY STRATEGY

15 DATA CITATIONS

LIST OF TABLES

  • TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
  • TABLE 2 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 3 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 4 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 5 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 6 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 7 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 8 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY REGION, 2019-2035 (USD MILLION)
  • TABLE 9 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 10 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 11 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 12 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 13 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 14 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 15 US DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 16 US DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 17 US DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 18 US DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 19 US DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 20 US DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 21 CANADA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 22 CANADA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 23 CANADA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 24 CANADA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 25 CANADA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 26 CANADA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 27 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 28 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 29 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 30 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 31 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 32 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 33 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 34 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 35 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 36 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 37 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 38 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 39 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 40 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 41 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 42 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 43 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 44 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 45 UK DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 46 UK DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 47 UK DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 48 UK DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 49 UK DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 50 UK DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 51 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 52 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 53 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 54 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 55 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 56 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 57 ITALY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 58 ITALY DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION
  • TABLE 59 ITALY DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 60 ITALY DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 61 ITALY DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 62 ITALY DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 63 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 64 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 65 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 66 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION
  • TABLE 67 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 68 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 69 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 70 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 71 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 72 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 73 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 74 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 75 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 76 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 77 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 78 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 79 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 80 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 81 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 82 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 83 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 84 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 85 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 86 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 87 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 88 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 89 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 90 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 91 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 92 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 93 CHINA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 94 CHINA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 95 CHINA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 96 CHINA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 97 CHINA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 98 CHINA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 99 INDIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 100 INDIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 101 INDIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 102 INDIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 103 INDIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 104 INDIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 105 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 106 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 107 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 108 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 109 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 110 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 111 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 112 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 113 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 114 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 115 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 116 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 117 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 118 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 119 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 120 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 121 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 122 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 123 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 124 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 125 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 126 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 127 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 128 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 129 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 130 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 131 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 132 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 133 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 134 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 135 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 136 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 137 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 138 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 139 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 140 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 141 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 142 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 143 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 144 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 145 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 146 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 147 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 148 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 149 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 150 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 151 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 152 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 153 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 154 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 155 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 156 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 157 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 158 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 159 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 160 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 161 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 162 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 163 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 164 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 166 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 168 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 169 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 170 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 171 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 172 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 173 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 174 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 175 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 176 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 177 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 178 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 179 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 180 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 181 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 182 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 183 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 184 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 185 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 186 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 187 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 188 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 189 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
  • TABLE 190 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
  • TABLE 191 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
  • TABLE 192 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
  • TABLE 193 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
  • TABLE 194 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  • TABLE 195 PFIZER. COMPANY: PRODUCTS OFFERED
  • TABLE 196 CIPLA LTD. PRODUCTS OFFERED
  • TABLE 197 GLAXOSMITHKLINE (GSK)/ PANADOL : PRODUCTS OFFERED
  • TABLE 198 JOHNSON & JOHNSON: PRODUCTS OFFERED
  • TABLE 199 APTARGROUP, INC. COMPANY: PRODUCTS OFFERED
  • TABLE 200 PROCTOR & GAMBLE COMPANY PRODUCTS OFFERED
  • TABLE 201 RECKITT BENCKISER GROUP PLC CHEMICAL LTD: PRODUCTS OFFERED
  • TABLE 202 SANOFI: PRODUCTS OFFERED
  • TABLE 203 PERRIGO COMPANY PLC: PRODUCTS OFFERED
  • TABLE 204 DR. REDDY'S LABORATORIES: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL DECONGESTANT MARKET (BY REGION), 2024
  • FIGURE 2 GLOBAL DECONGESTANT MARKET: STRUCTURE
  • FIGURE 3 PORTER'S FIVE FORCES ANALYSIS OF THE DECONGESTANT
  • FIGURE 4 GLOBAL DECONGESTANT MARKET, BY PRODUCT TYPE, 2024 (% SHARE)
  • FIGURE 5 GLOBAL DECONGESTANT MARKET, BY FORMULATION, 2024 (% SHARE)
  • FIGURE 6 GLOBAL DECONGESTANT MARKET, BY CATEGORY, 2024 (% SHARE)
  • FIGURE 7 GLOBAL DECONGESTANT MARKET, BY APPLICATION, 2024 (% SHARE)
  • FIGURE 8 GLOBAL DECONGESTANT MARKET, BY AGE GROUP, 2024 (% SHARE)
  • FIGURE 9 GLOBAL DECONGESTANT MARKET, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  • FIGURE 10 GLOBAL DECONGESTANT MARKET MAJOR PLAYERS MARKET SHARE ANALYSIS, 2024 (%)
  • FIGURE 11 PFIZER. COMPANY: SWOT ANALYSIS
  • FIGURE 12 CIPLA LTD. SWOT ANALYSIS
  • FIGURE 13 GLAXOSMITHKLINE (GSK)/ PANADOL : SWOT ANALYSIS
  • FIGURE 14 JOHNSON & JOHNSON: SWOT ANALYSIS
  • FIGURE 15 APTARGROUP, INC. COMPANY: SWOT ANALYSIS
  • FIGURE 16 PROCTOR & GAMBLE COMPANY SWOT ANALYSIS
  • FIGURE 17 RECKITT BENCKISER GROUP PLC CHEMICAL LTD: SWOT ANALYSIS
  • FIGURE 18 SANOFI: SWOT ANALYSIS
  • FIGURE 19 PERRIGO COMPANY PLC: SWOT ANALYSIS
  • FIGURE 20 DR. REDDY'S LABORATORIES: SWOT ANALYSIS